<DOC>
	<DOCNO>NCT02015507</DOCNO>
	<brief_summary>To evaluate effect ciprofloxacin pharmacokinetics ( PK ) ivacaftor pharmacokinetics VX-661 administer combination ivacaftor</brief_summary>
	<brief_title>An Open-Label , Phase 1 Study Healthy Adult Subjects Examine Effects Multiple-Dose Ciprofloxacin Ivacaftor VX-661 Combination With Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Willing able comply schedule visit , treatment plan , study restriction , laboratory test , contraception guideline , study procedure Healthy subject , define clinically relevant abnormality identify detailed medical history full physical examination , include blood pressure heart rate measurement , standard 12lead ECG , clinical laboratory test . Body mass index ( BMI ) 18.0 31.0 kg/m2 , inclusive , total body weight &gt; 50 kg Female subject childbearing potential must negative serum pregnancy test screen Day 1 Visit . History illness , clinical condition , factor , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug ( ) subject Inability swallow capsule , inadequate venous access . History febrile illness within 5 day first study drug dose A screen positive hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus 1 2 antibody . For female subject : Pregnant nursing subject female subject childbearing potential unwilling unable use acceptable method contraception outline protocol . For male subject : Subject female partner pregnant , nursing , plan become pregnant study within 120 day last study drug dose . Any condition possibly affect drug absorption Abnormal renal function screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>